Koronis Pharmaceuticals, Inc.

Koronis Pharmaceuticals, Inc. is focused on developing innovative antiviral technologies for the prevention and treatment of chronic viral diseases, particularly targeting HIV, HBV, and HCV with advanced therapeutic mechanisms. Founded in 1998, Koronis Pharmaceuticals, Inc. is headquartered in Seattle, US.

The company specializes in antiviral treatments and has undergone strategic pivots to enhance its research capabilities. Koronis has raised a total of USD 1. 0 mn through various funding rounds, with its most recent financing being a Venture Debt round in September 2015, securing USD 0. 06 mn.

Koronis Pharmaceuticals, Inc. specializes in the development of antiviral technologies aimed at chronic viral diseases, particularly HIV, HBV, and HCV. The company's primary product candidate, KP-1461, utilizes a novel therapeutic mechanism known as Viral Decay Acceleration™ (VDA) to promote viral mutation leading to viral collapse. In addition, Koronis has created Stealth Nucleosides™, which leverage viral mutagenesis to harness the inherent high mutation rate of various viruses.

The company’s target market includes healthcare providers and research institutions across North America and Europe. Koronis Pharmaceuticals generates revenue through partnerships with research institutions and pharmaceutical companies, primarily from clinical trials and technology licensing. Its key product, KP-1461, is currently undergoing clinical trials for HIV treatment, which could facilitate revenue generation upon successful commercialization through sponsorship agreements, licensing fees, and milestone payments. Although pricing structures are dependent on partnership agreements, specific pricing information has not been disclosed.

Koronis Pharmaceuticals plans to advance its product pipeline, specifically focusing on KP-1461 and additional antiviral treatments, aiming for new product launches within the next few years. The company is also targeting expansion into European markets to broaden its reach by 2025. The recent Venture Debt financing of USD 0. 06 mn will be utilized to support these growth initiatives, enhancing development efforts and expanding partnerships.